Humulin N (Insulin Human (Rdna))

Humulin N is indicated for the management of blood glucose in adults and children with diabetes when basal insulin coverage is required.

• Type 1 diabetes mellitus as part of a basal‑bolus regimen.
• Type 2 diabetes mellitus when oral agents or other insulins do not achieve target glycaemic control.
• Adjunct therapy during pregnancy or lactation when recommended by a healthcare professional.
• Use in combination with rapid‑acting insulin analogues for flexible dosing schedules.

• Humulin N contains recombinant human insulin that binds to the insulin receptor on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and inhibiting hepatic gluconeogenesis. The intermediate‑acting profile provides prolonged basal insulin activity and contributes to overall metabolic homeostasis by regulating lipid synthesis and protein metabolism.

Like all insulin preparations, Humulin N may cause adverse reactions ranging from mild injection‑site irritation to rare but serious systemic events.

Common

• Hypoglycemia (low blood glucose) – the most frequent effect.
• Injection‑site redness, swelling or itching.
• Lipodystrophy (localized fat loss or accumulation).
• Weight gain due to improved glucose utilization.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Edema or fluid retention, especially in patients with cardiac or renal disease.
• Hypersensitivity with eosinophilia or serum‑sickness‑like syndrome.

Healthcare professionals should assess individual risk factors before initiating Humulin N and monitor patients regularly for safety concerns.

• Adjust dose when renal or hepatic impairment is present.
• Use caution in patients with a history of severe hypoglycemia or unawareness.
• Review concomitant medications that may mask hypoglycemia symptoms.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Monitor weight, fluid status, and signs of edema during therapy.
• Pregnancy and lactation decisions should be guided by a prescriber.

Humulin N can interact with other drugs that affect glucose metabolism or insulin action, requiring dose adjustments or close monitoring.

Avoid

• Concurrent use of other rapid‑acting insulins without proper dose reduction.
• Combination with meglitinides or sulfonylureas that increase hypoglycemia risk.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms.
• Corticosteroids, thiazide diuretics, and oral contraceptives can raise insulin requirements.
• Alcohol consumption may potentiate hypoglycemia.
• ACE inhibitors or ARBs may enhance insulin sensitivity, affecting dose needs.